OPT Opthea
- 2.240
- +0.040+1.82%
- 2.240
- 0.0000.00%
Opthea News
Bell Potter Remains a Buy on Opthea Limited (CKDXF)
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Ultragenyx Pharmaceutical (RARE) and Opthea Limited Sponsored ADR (OPT)
Buy Rating for Opthea Limited on Promising Phase 2b Results of Sozinibercept for Wet AMD
Opthea Limited's Strong Financial Standing and Promising Drug Candidate Secure a Buy Rating: An Analysis by Chris Cooper
JonesTrading Sticks to Its Buy Rating for Opthea Limited Sponsored ADR (OPT)
Opthea Analyst Ratings
Oppenheimer Cuts Opthea Price Target to $16 From $31, Maintains Outperform Rating
Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN), Mirati Therapeutics (MRTX) and Opthea Limited Sponsored ADR (OPT)
H.C. Wainwright Remains a Buy on Opthea Limited Sponsored ADR (OPT)
HC Wainwright & Co. Reiterates Buy on Opthea, Maintains $14 Price Target
Opthea Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Opthea Limited (OtherCKDXF) and Glaukos (GKOS)
Analysts Offer Insights on Healthcare Companies: Opthea Limited Sponsored ADR (OPT) and Humacyte (HUMA)
EF Hutton Starts Opthea at Buy With $23 Price Target
EF Hutton Initiates Coverage On Opthea With Buy Rating, Announces Price Target of $23
Oppenheimer Adjusts Opthea's Price Target to $31 From $36, Maintains Outperform Rating
Oppenheimer Maintains Outperform on Opthea, Lowers Price Target to $31
Opthea Limited Sponsored ADR (OPT) Receives a Buy From SVB Securities
H.C. Wainwright Keeps Their Buy Rating on Opthea Limited Sponsored ADR (OPT)
HC Wainwright & Co. Reiterates Buy on Opthea, Maintains $14 Price Target
Analysis
Price Target
No Data
